OBJECTIVES: We sought to investigate the timing of restenosis and the restenosis factors following nitinol stenting in the superficial femoral artery (SFA). BACKGROUND: Restenosis following nitinol stenting in the SFA remains unsolved. METHODS: We analyzed 742 limbs in consecutive 585 patients who underwent successful endovascular therapy for de novo SFA lesions. Patency was assessed by duplex ultrasonography. Primary patency was defined as treated vessels without restenosis and secondary patency was defined as target vessels reopened by repeat revascularization. Receiver-operating characteristic (ROC) analysis was performed to delineate the timing of restenosis. Patients were subsequently classified into three groups: no restenosis, early restenosis, and late restenosis. Cox proportional hazard regression analyses were performed to explore the determinants of restenosis in each restenosis group. RESULTS: Primary and secondary patency was 67 and 86% at 6 years, respectively. ROC curves indicated the 369th day was the best cutoff point distinguishing the early (144 limbs) and the late (42 limbs) restenoses. Sustained patency was observed in 556 limbs. After multivariate analysis, cilostazol (P = 0.0007) was negatively associated; female gender (P = 0.0071), diabetes mellitus (P = 0.0428), critical limb ischemia (P = 0.0435), and stent fracture (P = 0.0004) were positively associated with the early restenosis. Trans Atlantic Inter-Society Consensus II C/D was positively associated with both the early (P = 0.0017) and the late (P = 0.0359) restenoses. CONCLUSIONS: Restenosis predominantly occurred within a year following nitinol stenting in the SFA, and the factors associated with the early restenosis were different from those with the late restenosis.
OBJECTIVES: We sought to investigate the timing of restenosis and the restenosis factors following nitinol stenting in the superficial femoral artery (SFA). BACKGROUND:Restenosis following nitinol stenting in the SFA remains unsolved. METHODS: We analyzed 742 limbs in consecutive 585 patients who underwent successful endovascular therapy for de novo SFA lesions. Patency was assessed by duplex ultrasonography. Primary patency was defined as treated vessels without restenosis and secondary patency was defined as target vessels reopened by repeat revascularization. Receiver-operating characteristic (ROC) analysis was performed to delineate the timing of restenosis. Patients were subsequently classified into three groups: no restenosis, early restenosis, and late restenosis. Cox proportional hazard regression analyses were performed to explore the determinants of restenosis in each restenosis group. RESULTS: Primary and secondary patency was 67 and 86% at 6 years, respectively. ROC curves indicated the 369th day was the best cutoff point distinguishing the early (144 limbs) and the late (42 limbs) restenoses. Sustained patency was observed in 556 limbs. After multivariate analysis, cilostazol (P = 0.0007) was negatively associated; female gender (P = 0.0071), diabetes mellitus (P = 0.0428), critical limb ischemia (P = 0.0435), and stent fracture (P = 0.0004) were positively associated with the early restenosis. Trans Atlantic Inter-Society Consensus II C/D was positively associated with both the early (P = 0.0017) and the late (P = 0.0359) restenoses. CONCLUSIONS:Restenosis predominantly occurred within a year following nitinol stenting in the SFA, and the factors associated with the early restenosis were different from those with the late restenosis.
Authors: Anna Corti; Monika Colombo; Jared M Rozowsky; Stefano Casarin; Yong He; Dario Carbonaro; Francesco Migliavacca; Jose F Rodriguez Matas; Scott A Berceli; Claudio Chiastra Journal: J R Soc Interface Date: 2022-03-30 Impact factor: 4.118
Authors: Ramya C Mosarla; Ehrin Armstrong; Yonatan Bitton-Faiwiszewski; Peter A Schneider; Eric A Secemsky Journal: J Soc Cardiovasc Angiogr Interv Date: 2022-08-20
Authors: Ehrin J Armstrong; Haseeb Saeed; Bejan Alvandi; Satinder Singh; Gagan D Singh; Khung Keong Yeo; David Anderson; Gregory G Westin; David L Dawson; William C Pevec; John R Laird Journal: J Endovasc Ther Date: 2014-02 Impact factor: 3.487
Authors: Peter A Schneider; John R Laird; Gunnar Tepe; Marianne Brodmann; Thomas Zeller; Dierk Scheinert; Christopher Metzger; Antonio Micari; Ravish Sachar; Michael R Jaff; Hong Wang; Melissa S Hasenbank; Prakash Krishnan Journal: Circ Cardiovasc Interv Date: 2018-01 Impact factor: 6.546
Authors: Karen L Walker; Daniel B Walsh; Philip P Goodney; Samantha A Connell; David H Stone; Richard J Powell; Eva M Rzucidlo Journal: BMC Cardiovasc Disord Date: 2014-12-11 Impact factor: 2.298